The authors are all members of the Australian Pfizer Sutent Advisory Board. Jayesh Desai is also member of the Novartis GIST Advisory Board, and has received speaking honoraria from Pfizer and Novartis. Howard Gurney is chair of Wyeth Torisel (RCC) Advisory Board and a member of the Bayer Nexavar Advisory Board. Nick Pavlakis has received speaking honoraria from Pfizer and Bayer. Grant A McArthur is a member of the Novartis GIST Advisory Board. Ian D Davis is also chair of the Bayer Nexavar Advisory Board and a member of the Wyeth Torisel (RCC) Advisory Board, with all payments for his work donated to the Austin Hospital Medical Research Foundation to support research into urologic cancers. The information in this paper was collected, analyzed and interpreted by the authors. Pfizer was not involved in the preparation of the paper, but had the opportunity to review and approve the paper before it was submitted.
1743-7563/asset/AJCO_left.gif?v=1&s=71de41616b0113387df045a2cd3ec434e7fc7ba1)
Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: Recommendations for patient management†
Article first published online: 3 DEC 2007
DOI: 10.1111/j.1743-7563.2007.00136.x
Additional Information
How to Cite
DESAI, J., GURNEY, H., PAVLAKIS, N., McARTHUR, G. A. and DAVIS, I. D. (2007), Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: Recommendations for patient management. Asia-Pacific Journal of Clinical Oncology, 3: 167–176. doi: 10.1111/j.1743-7563.2007.00136.x
- †
Publication History
- Issue published online: 3 DEC 2007
- Article first published online: 3 DEC 2007
- Accepted for publication 15 October 2007.
- Abstract
- Article
- References
- Cited By
Keywords:
- gastrointestinal stromal tumor (GIST);
- multitargeted tyrosine kinase inhibitor (TKI);
- renal cell carcinoma (RCC);
- sunitinib
Abstract
Sunitinib malate (SU011248, Sutent®[Pfizer]) is an oral multitargeted tyrosine kinase inhibitor with efficacy against renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST). Sunitinib has been approved by various regulatory authorities for treatment of advanced RCC and unresectable and/or malignant GIST following failure of imatinib mesylate treatment due to resistance or intolerance. Sunitinib is generally well tolerated, with most side-effects being mild to moderate. The most common adverse events are lethargy, diarrhea, stomatitis, hand–foot syndrome and hypertension. Uncommon but important adverse effects are hypothyroidism and hematological toxicity (neutropenia and thrombocytopenia), which require monitoring. Caution is recommended when using concurrent inhibitors or inducers of CYP3A4. The frequency and severity of side-effects often correlates with increased drug exposure. In clinical trials, side-effects seldom led to treatment discontinuation. This paper summarizes the published literature and provides recommendations for patient assessments and management of treatment-related side-effects.